The purpose of this study was to investigate whether the administration of etanercept to patients with severe asthma improved their asthma related quality of life and a measure of the degree of reactivity of the airways
Although steroid dependent asthma represents a small population of patients with asthma, they consume a disproportionately large amount of the health resource burden attributed to asthma. Treatment options in this group are extremely limited; the development of effective treatments for this group of patients should be a priority, not only for increasing individual patient quality of life but for long term reduction of health spending. This randomised, double blind, placebo controlled, cross over trial will investigate the efficacy of a soluble TNF receptor, etanercept, in severe, steroid dependant asthma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
10
Institute for Lung Health
Leicester, Leicestershire, United Kingdom
Methacholine PC20
Juniper asthma quality of life
Net change in post-bronchodilator FEV1
FEF25-75
FVC
symptom visual analogue score
exhaled nitric oxide concentration
computed alveolar nitric oxide concentration
sputum differential inflammatory cell counts
sputum supernatant mediator concentration.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.